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The study was conducted at the French National Registry of  Childhood Solid Tumor, University Hospital Nancy, in France. It observed adolescent patients (15-19 years of  age), living in one of  the six French administrative regions, 
diagnosed with any type of  cancer or with Central Nervous System tumor between 
January 1, 2006, and December 31, 2007. 
Each patient’s data was collected from their medical records, and included 
gender, age at diagnosis, type of  cancer, time to diagnosis, time to start the treatment, 
management in the context of  a multidisciplinary decisional approach, inclusion in 
clinical studies and the type of  cancer treatment center (adult or pediatric). The initial 
time was the date of  the diagnosis and the final time was considered the death event. 
The length of  follow-up ranged from 0 to 84 months, averaging 69 months.
Several previous studies have shown that adolescents and young adults treated 
at a pediatric oncology center have better survival outcomes than those treated at 
an adult oncology facility. The  objectives of  the study were to identify which factors 
influence the access to each type of  care (adult and pediatric) and which determine the 
effect of  the treatment center on survival rates. 
Along two years of  study, 594 patients aged 15-19 years were diagnosed with 
cancer. Of  this total, 33% were managed at a pediatric center and 67% at an adult 
center. The study shows that younger patients were more likely to be treated at a 
pediatric center, while older patients were more likely to be treated at an adult center. 
Adolescents with sarcoma or leukemia were more likely to be treated at a 
pediatric center, while patients with carcinoma/melanoma or germ-cell tumor were 
more likely to be treated at an adult center. The proportional of  metastatic tumors and 
intracranial or intraspinal embryonal tumors (including tumors associated with poor 
outcomes) was higher for patients treated at pediatric centers than those treated at 
adult centers. 
The proportion of  males and females was the same. Adolescents with central 
nervous system tumor managed at an adult center had a longer time to diagnosis. 
For all cancers taken together, no differences were observed for time to treatment. 
However, adolescents with leukemia and lymphoma had a shorter time to treatment 
when they were treated at a pediatric center. Management decisions, especially the 
decision to initiate treatment, were taken by a multidisciplinary team in 53,9% of  
cases (the percentage was higher for patients treated at pediatric centers). Adolescents 
treated at pediatric centers were more frequently included in clinical studies.
Adolescents have a better 





































1. Desandes E, Lacour B, Sommelet D, Danzon A, Delafosse P, Grosclaude P et al. Cancer survival 
among adolescents in France. European Journal of  Cancer. 2006;42(3):403-409. 
2. Lacour B, Goujon S, Guissou S, Guyot-Goubin A, Desmée S, Désandes E et al. Childhood cancer 
survival in France, 2000–2008. European Journal of  Cancer Prevention. 2014;23(5):449-457.
3. Bleyer A, Ferrari A, Whelan J, Barr R. Global assessment of  cancer incidence and survival in 
adolescents and young adults. Pediatric Blood & Cancer. 2017;64(9):e26497. 
4. Lantigua C. Nathan and Oski’s hematology of  infancy and childhood. Philadelphia (Pa.): Saunders 
Elsevier; 2009.
At the end of  the follow up, 107 adolescents (18%) died on an average rate of  22 
months (between diagnosis and death). For all cancers of  any site, the overall survival 
was 94,1% at 1 year and 81,9% at 5 years. High 5-year overall survival was observed for 
Germ cell tumor, carcinomas and melanomas, Hodgkin lymphomas, central nervous 
system tumors, and Non Hodgkin lymphoma. Low 5 year overall survival was observed 
for malignant bone tumors, acute myeloid leukemia, and soft tissue sarcomas.
Unlike previous studies, the article shows that the overall survival rates for 
adolescent patients diagnosed with any kind of  cancer treated at a pediatric center or 
adult center did not differ. The 5-years overall survival in adolescents has improved 
form 72% during the 1988-1997 period to 81,2% during the study period.
Commentary by: Luiza Feuillatey Albagli, MD.
Pediatric Hematologist, Master Student at IPPMG/UFRJ.
The better survival rates over time probably can be justified by the improvement 
of  chemotherapy, the new technologies and a more prepared intensive care.
In this study, patients were not stratified by the prognostic risk; they were 
heterogeneous in relation to the risk classification. Therefore, the chance of  death was 
not the same for all the patients, even the ones with the same cancer. This may disrupt 
the results, because if  the majority of  patients with worse prognosis were treated at the 
pediatric center, the overall survival of  this treatment center would be lower. Besides 
that, the relatively small number of  patients (594 cases) over a short period of  study 
(2006-2007), limited the power of  the analysis. 
Although the study has not covered all the country, 41% of  the whole country 
is a good sample. The time of  the follow up is adequate because the average was 69 
months (5,7 years) and the authors want to see the overall survival in 5 years. 
This study was very important because adolescents are a special group in all 
the types of  cancer, since they do not have special treatment protocols as children and 
adults have. In general, they have a worse prognosis compared with children and they 
can be treated in pediatric or adult oncology centers. We must therefore give special 
attention to this group, by conducting more studies to understand its peculiarities and 
to find the best treatment.
